Menu Search
Equities

Novo Nordisk A/S

NOVO B:CPH

Novo Nordisk A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)778.60
  • Today's Change2.10 / 0.27%
  • Shares traded404.16k
  • 1 Year change+19.99%
  • Beta0.8008
Data delayed at least 15 minutes, as of Aug 16 2022 13:43 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Forecasts data is unavailable for this security.

Consensus recommendation

  • 19-Aug-21
  • 19-May-22
  • 16-Jun-22
  • 14-Jul-22
  • 11-Aug-22
Select bar for recommendation details.
Recommendations11-Aug-22
Buy6
Outperform11
Hold10
Underperform3
Sell2

Share price forecast in DKK

The 29 analysts offering 12 month price targets for Novo Nordisk A/S have a median target of 895.00, with a high estimate of 1,025.00 and a low estimate of 392.00. The median estimate represents a 15.26% increase from the last price of 776.50.
High32.0%1,025.00
Med15.3%895.00
Low-49.5%392.00

Dividends in DKK

In 2021, Novo Nordisk A/S reported a dividend of 10.40 DKK, which represents a 14.29% increase over last year. The 27 analysts covering the company expect dividends of 11.82 DKK for the upcoming fiscal year, an increase of 13.61%.
Div growth (TTM)14.29%
More ▼

Earnings history & estimates in DKK

On Aug 03, 2022, Novo Nordisk A/S reported 2nd quarter 2022 earnings of 5.86 per share. This result was in line with the consensus of the 12 analysts following the company and exceeded last year's 2nd quarter results by 11.41%.
The next earnings announcement is expected on Nov 02, 2022.
Average growth rate+3.85%
Novo Nordisk A/S reported annual 2021 earnings of 20.74 per share on Feb 02, 2022.
Average growth rate+7.86%
More ▼

Revenue history & estimates in DKK

Novo Nordisk A/S had 2nd quarter 2022 revenues of 41.27bn. This missed the 41.40bn consensus estimate of the 13 analysts following the company. This was 22.07% above the prior year's 2nd quarter results.
Average growth rate+5.81%
Novo Nordisk A/S had revenues for the full year 2021 of 140.80bn. This was 10.91% above the prior year's results.
Average growth rate+6.06%
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.